Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections

Sumonrat Chuwongwattana1,2 | Thawinee Jantararoungtong1,2 | Santirat Prommas1,2 | Sadeep Medhasi3 | Apichaya Puangpetch1,2 | Chonlaphat Sukasem1,2

1Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
2Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, Thailand
3Center for Medical Genomics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Correspondence
Chonlaphat Sukasem, Division of Pharmacogenetics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. Email: chonlaphat.suk@mahidol.ac.th

Funding information
International Research Network-The Thailand Research Fund, Grant/Award Number: IRN60W003; Faculty of Medicine, Ramathibodi Hospital, Mahidol University

Abstract
Voriconazole is the first-line antifungal choice in the treatment of invasive fungal infections (IFIs). Single nucleotide polymorphisms (SNPs) in drug-metabolizing and transporter genes may affect voriconazole pharmacokinetics. This study aimed to determine the frequency of the CYP2C19 rs4244285, rs4986893, rs72552267, and rs12248560, CYP3A4 rs4646437, ABCB1 rs1045642, and FMO3 rs2266782 alleles and determine the association between these genetic variants and voriconazole concentrations in Thai patients with invasive fungal infections. The study comprised 177 Thai patients with IFIs in whom seven SNPs in CYP2C19, CYP3A4, ABCB1, and FMO3 were genotyped using TaqMan real-time polymerase chain reaction (RT-PCR) 5’ nuclease assays, and voriconazole plasma concentrations were measured by high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS). Of the 177 patients included, 31 were <12 years and 146 were ≥12 years. The CYP2C19 allele frequencies were 0.29 for *2, 0.060 for *3, 0.003 for *6, and 0.008 for *17. The allele frequency of CYP3A4 (rs4646437) was 0.26, ABCB1 (rs1045642) was 0.36, and FMO3 (rs2266782) was 0.16. The median voriconazole dose/weight was significantly lower in patients aged ≥12 years when compared to the patients aged <12 years (P < .001). Patients aged <12 years with CYP2C19*1/*2 exhibited significantly higher median voriconazole plasma concentrations than those with the CYP2C19*1/*1 (P = .038). However, there were no significant differences in median voriconazole plasma concentrations among the CYP2C19 genotypes in the patients aged ≥12 years. There was a lack of association observed among the CYP3A4, ABCB1, and FMO3 genotypes on the plasma voriconazole concentrations in both groups of patients. Our findings indicate that voriconazole plasma concentrations are affected by the CYP2C19*2 allele in patients aged <12 years but not in patients aged ≥12 years.
1 | INTRODUCTION

Voriconazole is a second-generation triazole with broad-spectrum spectrum antifungal activity against Aspergillus, fluconazole-resistant Candida, Fusarium, and Scedosporium species. It is used as a first-line treatment for invasive fungal infections (IFIs). Voriconazole is characterized by a narrow therapeutic range, significant inter- and intrapatient pharmacokinetic variability, and nonlinear pharmacokinetics. Voriconazole exhibits significant exposure-response relationships for efficacy and toxicity, which is why therapeutic drug monitoring (TDM) is now widely recommended to optimize clinical outcomes. Previous studies have reported an optimal voriconazole concentration of 1.0-5.5 µg/mL for improved outcomes and minimal toxicities.

Voriconazole is metabolized by the hepatic cytochrome P450 isoenzymes, CYP2C19, CYP2C9, and CYP3A4. Flavin-containing monooxygenase 3 (FMO3), an oxidative drug-metabolizing enzyme, also contributes to the metabolism of voriconazole. CYP2C19 polymorphism, age of the individual, liver function, and coadministration of drugs that modulate its activities may affect voriconazole plasma concentrations. Genetic variations in the metabolizing enzyme CYP2C19 are one of the major determinants of the voriconazole blood level. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has provided therapeutic recommendations for the use of voriconazole based on CYP2C19 genotype for pediatric and adult patients. Two CYP2C19 alleles, rs4244285 (CYP2C19*2, c.681G > A) and rs4986893 (CYP2C19*3, c.636G > A), decrease the enzyme activity by the quantitative reduction of enzyme protein and have been reported to result in approximately fourfold higher plasma exposure to voriconazole than CYP2C19*1 carriers. The CYP2C19*17 (c.-806C > T, rs12248560) allele is associated with increased enzyme activity and has been associated with therapeutic failure with voriconazole. The CYP2C19*6 (c.395G > A, rs72552267) is a no function allele with frequency <0.5% in major ethnic groups. CYP3A4 enzyme is the most abundant in human liver and plays an important role in oxidative metabolism of clinical drugs in adult liver. Voriconazole is catalyzed more efficiently by CYP3A4 than CYP3A5. The rs4646437 single-nucleotide polymorphism (SNP) of the CYP3A4 was associated with higher plasma voriconazole concentrations in a study cohort of Chinese patients with IFIs. Allegra et al reported an association between the ABCB1 (c.3435C > T, rs1045642) SNP and trough concentration of voriconazole. The study found that the genotype TT was associated with a decreased trough concentration of voriconazole in children as compared to genotypes CC and CT. FMOs, mainly the FMO3 enzyme, have an important role in voriconazole metabolism that have been reported in the several studies, especially among children. In vitro study suggested a contribution of approximately 25% of FMO3 enzyme might affect voriconazole metabolism. To our knowledge, the influence of FMO3 genetic polymorphisms on the pharmacokinetic parameters of voriconazole in invasive fungal infection patients remains unclear. Voriconazole showed decreased activity. This variation was reported in multiple populations, including Caucasians, Asians and African-Americans. Yamada et al reported an association between FMO3 rs2266782 (E158K) and trough concentration of voriconazole.

Based on these observations, we sought to determine the frequency of the CYP2C19 rs4244285, rs4986893, rs72552267, and rs12248560, CYP3A4 rs4646437, ABCB1 rs1045642, and FMO3 rs2266782 polymorphisms in a Thai population and to determine the association between voriconazole plasma concentrations and these genetic variants in Thai patients with invasive fungal infections.

2 | MATERIALS AND METHODS

2.1 | Patients

This was a retrospective study of 177 Thai invasive fungal-infected patients receiving voriconazole treatment from January 2013 to December 2015 at Ramathibodi Hospital (Bangkok, Thailand). All patients were started on standard voriconazole dosing either oral or intravenous administration every 12 hours. For intravenous (IV) dose, patients received voriconazole at a loading dose of 6 or 8 mg/kg/dose twice on the first day of treatment, then 4 or 6 mg/kg/dose twice daily. For oral (PO) dose, the recommended dose of voriconazole was 100 mg twice daily for a patient with body weights less than 40 kg and 200 mg twice daily for more than 40 kg.

Inclusion criteria included all of the following: diagnosis of invasive fungal infection, treatment with voriconazole, and with at least one steady-state voriconazole trough concentration. Exclusion criteria were as follows: current pregnancy, allergy to voriconazole, and ethnicity other than Thai. Patient medical records were individually reviewed using a standardized data collection template. Collected data included demographic information and clinical information regarding the voriconazole dosing and delivery route, concomitant medications taken during voriconazole therapy, treatment response, and adverse events.

The study protocol was approved by the Hospital Ethics Committee of Ramathibodi Hospital, Mahidol University. All patients provided written informed consent. This study is registered in the Voriconazole Registry-Prospective cohort.

2.2 | Genotyping assay

Genomic DNA was extracted from EDTA blood sample using a MagNA Pure LC DNA Isolation Kit following the manufacturer’s
protocol (Roche, Mannheim, Germany). Genomic DNA was quantified using NanoDrop ND-1000 Spectrophotometer (Thermo Fisher Scientific, DE, USA). Genomic DNA was then frozen at -20°C until the time of genotyping.

Genotyping was performed by allelic discrimination using TaqMan real-time polymerase chain reaction (RT-PCR) 5′ nuclease assays. Allelic discrimination was carried out by measuring endpoint fluorescence intensity with a Viia™ 7 RT-PCR System (Applied Biosystems, Foster City, California).

2.3 Blood sampling and analytical assays

Blood samples were taken in steady-state one hour before voriconazole administration. Voriconazole trough plasma concentrations were determined using validated high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS). All intra- and interday accuracy (%) and precision (%CV) measurements were within acceptable ranges recommended by the US-FDA guidelines for bioanalytical method validation. The lower limit of quantification (LLOQ) for voriconazole was 0.05 µg/mL. The intra- and interday accuracies were 95.30 ± 3.41% and 87.80 ± 6.58%, respectively. The intra- and interday precision (%CV) were 7.2% and 7.9%, respectively.

2.4 Statistical analysis

Continuous data are presented as mean and standard deviations, and categorical data are expressed as frequencies and percentages. Conformity to Hardy-Weinberg equilibrium (HWE) was determined using Fisher’s exact test. Kruskal-Wallis and Mann-Whitney tests were used to determine the influence of genetic polymorphisms on voriconazole plasma concentrations, and the correlation of age with dose and plasma concentrations of voriconazole. A two-sided P-value less than .05 was considered statistically significant. Statistical analyses were performed using the SPSS software package (SPSS version 18.0 for Windows, SPSS Inc, Chicago, IL).

3 RESULTS

3.1 Patient characteristics

The demographics and clinical characteristics of recruited patients (n = 177) are summarized in Table 1. Patients were categorized based on the age group (age <12 years, age ≥12 years). Thirty-one patients were aged <12 years, and 146 were ≥12 years. The mean (SD) age of the patients aged <12 years was 5.00 years (2.93 years) and ≥12 years was 48.82 years (21.01 years). The mean (SD) body weight in patients aged <12 years was 21.36 kg (11.24 kg) and ≥12 years was 55.83 kg (11.28 kg). Most of the patients had hematological disorders (<12 years, n = 22 (70.97%) and ≥12 years, n = 73 (50%)). The median dose (mg/kg) of voriconazole was 7.894 mg/kg in patients aged <12 years and 4 mg/kg in ≥12 years. Voriconazole was used by 96.77% of patients aged <12 years for possible invasive pulmonary aspergillosis (IPA). Meanwhile, only 19.86% of patients aged ≥12 years used voriconazole for possible IPA, 47.26% for probable IPA, and 28.08% for proven IPA. Although, voriconazole was also prescribed for 4.80% of patients aged <12 years with no IPA. Seventeen (54.84%) patients received voriconazole intravenously and 14 (45.16%) orally in patients aged <12 years. In patients aged ≥12 years, 116 (79.45%) received voriconazole orally and 30 (20.55%) intravenously.

Table 1 Baseline characteristics of the patients categorized by age (n = 177)

| Characteristics | Age <12 years (N = 31) | Age ≥12 years (N = 146) |
|-----------------|------------------------|-------------------------|
| Sex Male        | 23 (74.19%)            | 66 (45.21%)             |
| Female          | 8 (25.81%)             | 80 (54.79%)             |
| Age             | 5.00 ± 2.93            | 48.82 ± 21.01           |
| Weight (Mean ± SD) | 21.36 ± 11.24         | 55.83 ± 11.28           |
| Underlying disease |                        |                         |
| Hematological disorder | 22 (70.97%) | 73 (50.00%) |
| Lymphoma        | 2 (6.45%)              | 19 (13.01%)             |
| Diabetes        | 0 (0)                  | 12 (8.22%)              |
| SLE             | 0 (0)                  | 11 (7.53%)              |
| Thalassemia     | 0 (0)                  | 3 (2.05%)               |
| Malignant       | 4 (12.90%)             | 0 (0)                   |
| Cancer          | 0 (0)                  | 2 (1.37%)               |
| Hypertension    | 0 (0)                  | 2 (1.37%)               |
| Others          | 2 (6.45%)              | 19 (13.01%)             |
| None            | 1 (3.23%)              | 5 (3.42%)               |
| Drug dose/body weight (Median (IQR), mg/kg) | 7.894 (5.970-9.000) | 4.000 (3.633-4.545) |
| Type of IPA     |                        |                         |
| Possible IPA    | 30 (96.77%)            | 29 (19.86%)             |
| Probable IPA    | 1 (3.23%)              | 69 (47.26%)             |
| Proven IPA      | 0 (0)                  | 41 (28.08%)             |
| No IPA          | 0 (0)                  | 7 (4.80%)               |
| Route of administration |                  |                         |
| Intravenous     | 17 (54.84%)            | 30 (20.55%)             |
| Oral            | 14 (45.16%)            | 116 (79.45%)            |
| Infection site  |                        |                         |
| Pulmonary       | 31 (100%)              | 118 (80.82%)            |
| Extra pulmonary | 0 (0)                  | 28 (19.18%)             |
3.2 | Allelic frequency of the variants in a Thai population treated with voriconazole

The frequencies of the variants in CYP2C19, CYP3A4, ABCB1, and FMO3 are shown in Table 2. CYP2C19 allele frequencies were 0.29 for *2, 0.060 for *3, 0.003 for *6, and 0.008 for *17. The allele frequency of CYP3A4 (rs4646437) was 0.26, ABCB1 (rs1045642) was 0.36, and FMO3 (rs2266782) was 0.16. The allele frequencies of all the variants were in Hardy-Weinberg equilibrium (P > .05).

3.3 | Influence of CYP2C19 genotypes on plasma voriconazole concentrations

The association of CYP2C19 polymorphisms with voriconazole dose and voriconazole plasma concentrations in Thai patients with invasive fungal infections is shown in Table 3. There was considerable interindividual variability in voriconazole trough concentrations among the patients aged <12, which ranged from 1.13 μg/mL to 5.13 μg/mL. Patients aged <12 years with CYP2C19*1/*2 exhibited significantly higher median voriconazole plasma concentrations than those with the CYP2C19*1/*1 (P = .038). CYP2C19*2/*2 was not associated with increased trough levels versus CYP2C19*1/*1 (P = .312) among the patients aged <12 years. CYP2C19*17 allele was not detected among the patients aged <12 years. No significant differences were observed in median voriconazole doses among the CYP2C19 genotypes in the patients aged <12 years.

There were no significant differences in median voriconazole plasma concentrations among the CYP2C19 genotypes in the patients aged ≥12 years. The median voriconazole level ranged from 0.60 μg/mL to 2.7 μg/mL in the patients aged ≥12 years. In patients aged ≥12 years, only one patient had CYP2C19*2/*17 genotype and the trough concentration out of therapeutic range (<1 μg/mL). No significant differences were observed in median voriconazole doses among the CYP2C19 genotypes in the patients aged ≥12 years. The median voriconazole dose/weight was almost double in patients aged <12 years compared to patients aged ≥12 years (7.89 mg/kg vs 4.00 mg/kg).

3.4 | Influence of CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole concentrations

There was a lack of association observed among the CYP3A4, ABCB1, and FMO3 genotypes on the plasma voriconazole concentrations in both groups of patients as shown in Table 4. In patients aged <12 years, CYP3A4 rs4646437 CT (n = 16) genotype showed a median voriconazole level of 4.363 μg/mL (IQR: 1.082-7.510 μg/mL), which was relatively higher compared to CC (n = 14) and TT (n = 1) genotypes. Although not statistically significant, the median voriconazole dose was relatively higher in the CYP3A4 rs4646437 CT genotype among the patients aged <12 years (Table 4). FMO3 rs2266782 AA genotype was not observed among the patients aged <12 years.

| Gene          | rs number       | Polymorphisms | Genotype | No. (%) | Minor allele frequency |
|--------------|-----------------|---------------|----------|---------|-----------------------|
| CYP2C19*2    | rs4244285       | 681G > A      | GG       | 88 (49.72) | A = 0.290 |
|              |                 |               | GA       | 75 (42.37) |                       |
|              |                 |               | AA       | 14 (7.91)  |                       |
| CYP2C19*3    | rs4986893       | 636G > A      | GG       | 156 (88.14) | A = 0.060 |
|              |                 |               | GA       | 21 (11.86) |                       |
| CYP2C1*6     | rs72552267      | 395G > A      | GG       | 176 (99.44) | A = 0.003 |
|              |                 |               | GA       | 1 (0.57)   |                       |
| CYP2C19*17   | rs12248560      | −806C > T     | CC       | 174 (98.31) | T = 0.008 |
|              |                 |               | CT       | 3 (1.69)   |                       |
| CYP3A4       | rs4646437       | 671-202C > T  | CC       | 90 (66.10) | T = 0.26 |
|              |                 |               | CT       | 81 (30.51) |                       |
|              |                 |               | TT       | 6 (3.39)   |                       |
| ABCB1        | rs1045642       | 3435C > T     | CC       | 75 (42.37) | T = 0.36 |
|              |                 |               | CT       | 78 (44.07) |                       |
|              |                 |               | TT       | 24 (13.56) |                       |
| FMO3         | rs2266782       | G > A         | GG       | 129 (72.89) | A = 0.16 |
|              |                 |               | GA       | 41 (23.16)  |                       |
|              |                 |               | AA       | 7 (3.95)    |                       |

Table 2: The minor allele frequencies of pharmacokinetics and transporter in Thai patients with invasive fungal infections (n = 177).
TABLE 3 Median initial voriconazole dose and voriconazole trough concentration (μg/mL) stratified by CYP2C19 polymorphisms in Thai patients with invasive fungal infections (n = 177)

| Gene polymorphism     | Frequency (%) | Median voriconazole dose (mg/kg) (IQR) | P-value* | Median Voriconazole level (μg/mL) (IQR) | P-value* |
|-----------------------|--------------|----------------------------------------|----------|----------------------------------------|----------|
| Patients < 12 years   |              |                                        |          |                                        |          |
| CYP2C19*1/*1          | 12 (38.71)   | 7.98 (6.73-9.29)                       | Ref.     | 1.130 (0.516-3.894)                    | Ref.     |
| CYP2C19*1/*2          | 12 (38.71)   | 7.61 (5.93-9.71)                       | 1.000    | 4.271 (2.066-7.716)                    | 0.038*   |
| CYP2C19*1/*3          | 3 (9.68)     | 7.89 (7.52-8.58)                       | 0.885    | 5.125 (2.959-6.040)                    | 0.312    |
| CYP2C19*2/*2          | 3 (9.68)     | 7.14 (6.30-7.66)                       | 0.427    | 3.793 (2.436-4.008)                    | 0.386    |
| CYP2C19*2/*3          | 1 (3.23)     | 4.69                                   | 0.109    | 2.523                                  | 0.593    |
|                       | 31 (100.00)  | 7.89 (5.97-9.00)                       | 0.517    | 2.726 (0.898-6.956)                    | 0.288    |
| Patients ≥ 12 years   |              |                                        |          |                                        |          |
| CYP2C19*1/*1          | 59 (40.41)   | 3.80 (3.43-4.56)                       | Ref.     | 2.020 (0.236-0.856)                    | Ref.     |
| CYP2C19*1/*2          | 55 (37.67)   | 4.00 (3.70-4.44)                       | 0.223    | 2.340 (0.205-0.980)                    | 0.244    |
| CYP2C19*1/*3          | 12 (8.22)    | 4.04 (3.89-4.36)                       | 0.315    | 2.380 (0.117-1.606)                    | 0.524    |
| CYP2C19*2/*17         | 1 (0.68)     | 7.55                                   | 0.088    | 0.604                                  | 0.388    |
| CYP2C19*2/*2          | 11 (7.53)    | 4.22 (3.84-4.68)                       | 0.188    | 2.703 (0.213-1.116)                    | 0.540    |
| CYP2C19*2/*3          | 5 (3.42)     | 3.80 (3.66-4.17)                       | 0.793    | 2.585 (0.252-1.340)                    | 0.613    |
| CYP2C19*2/*6          | 1 (0.68)     | 2.99                                   | 0.194    | 2.520                                  | 0.260    |
| CYP2C19*1/*17         | 2 (1.37)     | 4.03 (3.39-4.67)                       | 0.903    | 2.665 (0.250-1.227)                    | 0.624    |
|                       | 146 (100.00) | 4.00 (3.63-4.54)                       | 0.327    | 2.105 (0.870-3.887)                    | 0.864    |

Note: Ref. = Reference (CYP2C19*1/*1, wild type).

*P-value was calculated using Kruskal-Wallis and Mann-Whitney U test. Comparison with CYP2C19 *1/*1.
*P-value < 0.05.

3.5 | Relationship of age with dose and plasma concentrations of voriconazole

Figure 1 shows the relationships of the age with the dose and the trough plasma concentrations of voriconazole. The median voriconazole doses in patients aged <12 years and patients aged ≥12 years were 7.89 mg/kg (IQR: 5.97-9.00 mg/kg) and 4.00 mg/kg (IQR: 3.63-4.54 mg/kg), respectively. The median voriconazole dose/weight was significantly lower in patients aged ≥12 years when compared to the patients aged <12 years (P < .001). The median voriconazole trough concentrations in patients aged <12 years and patients aged ≥12 years were 2.726 μg/mL (IQR: 0.898-6.956 μg/mL) and 2.105 μg/mL (0.870-3.887 μg/mL), respectively. There was no statistically significant difference in plasma voriconazole concentrations between the two age groups (P = .163).

4 | DISCUSSION

In this study, we investigated the association of SNPs in CYP2C19, CYP3A4, ABCB1, and FMO3 and the plasma concentrations of voriconazole in Thai patients with invasive fungal infections. Also, the allele frequency of these variants in the Thai population was obtained. The results demonstrated that CYP2C19 rs4244285 was associated with increased plasma concentrations of voriconazole in "1/2 genotype when compared to the wild type *1/*1 genotype in patients aged <12 years. This finding indicates that rs4244285 may be accountable for the susceptibility to changes in the plasma voriconazole concentrations. To our knowledge, this report is the first to analyze the involvement of CYP2C19, CYP3A4, FMO3, and ABCB1 variants that affects the plasma concentrations of voriconazole in Thai patients.

Voriconazole, an approved treatment for IFIs, exhibits nonlinear pharmacokinetics and is primarily metabolized by hepatic cytochrome P450 (CYP) enzymes 2C19 (CYP2C19) and CYP3A4. Genetic polymorphisms in CYP2C19 play an important role in the wide interindividual variability in voriconazole pharmacokinetics. In a population of 106 South-western Chinese Han patients, voriconazole dose-corrected predose concentration (C₀/dose) was significantly influenced by the CYP2C19 genotype. The voriconazole C₀/dose was significantly associated with the CYP2C19*2 (rs4244285) polymorphism. CYP2C19*1 represents the wild type allele. The CYP2C19*2 (c.681G > A; rs4244285) loss-of-function allele is responsible for the CYP2C19 "poor-metabolism" phenotype. The CYP2C19*2 allele, a synonymous G > A transition in exon 5, creates an aberrant splice site and alters the mRNA reading frame, which results in a truncated, nonfunctional protein. The frequencies of CYP2C19*2 are approximately 12% in Caucasians, 15% in African-Americans, and 29%-35% in Asians. The frequency of CYP2C19*2 in our study was found to be 29% and agrees with the data published earlier by Sukasem...
**TABLE 4** Association between genetic polymorphisms with voriconazole dose (mg/kg) and initial voriconazole trough concentration (µg/mL) in Thai patients with invasive fungal infections (n = 177)

| Gene polymorphism | Frequency (%) | Median voriconazole dose mg/kg (IQR) | P-value<sup>a</sup> | Median Voriconazole level (µg/mL) (IQR) | P-value<sup>a</sup> |
|-------------------|--------------|--------------------------------------|--------------------|-----------------------------------------|--------------------|
| **Patients < 12 years (N = 31)** | | | | | |
| CYP3A4(rs4646437) | | | | | |
| CC | 14 (45.16) | 6.72 (5.85-8.15) | Ref. | 1.633 (0.989-3.406) | Ref. |
| CT | 16 (51.61) | 8.03 (7.04-8.78) | 0.178 | 4.363 (1.082-7.510) | 0.125 |
| TT | 1 (3.23) | 4.09 | 0.108 | 2.406 | 0.789 |
| ABCB1(rs1045642) | | | | | |
| 3435C > T | | | | | |
| CC | 12 (38.71) | 7.14 (6.14-8.03) | Ref. | 3.793 (1.403-5.729) | Ref. |
| CT | 14 (45.16) | 7.14 (5.97-8.28) | 0.401 | 1.600 (0.898-4.223) | 0.977 |
| TT | 5 (16.13) | 8.33 (7.14-9.00) | 0.571 | 5.063 (2.773-6.956) | 0.364 |
| FMO3 (rs2266782) | | | | | |
| G > A | | | | | |
| GG | 24 (77.42) | 7.51 (5.97-8.28) | Ref. | 2.464 (0.794-4.503) | Ref. |
| GA | 7 (22.58) | 7.14 (6.30-8.66) | 0.919 | 5.063 (2.651-8.861) | 0.133 |
| **Patients ≥ 12 years (N = 146)** | | | | | |
| CYP3A4(rs4646437) | | | | | |
| CC | 76 (52.05) | 3.90 (3.63-4.54) | Ref. | 2.105 (0.960-3.533) | Ref. |
| CT | 65 (44.52) | 3.93 (3.43-4.44) | 0.480 | 2.440 (0.750-4.690) | 0.630 |
| TT | 5 (3.43) | 4.54 (4.21-4.65) | 0.232 | 1.900 (1.350-2.340) | 0.878 |
| ABCB1(rs1045642) | | | | | |
| 3435C > T | | | | | |
| CC | 63 (43.15) | 3.85 (3.57-4.70) | Ref. | 1.563 (0.605-3.795) | Ref. |
| CT | 64 (43.83) | 4.00 (3.63-4.44) | 0.919 | 2.320 (1.256-3.843) | 0.250 |
| TT | 19 (13.02) | 3.89 (3.38-4.28) | 0.436 | 1.293 (0.475-3.037) | 0.676 |
| FMO3 (rs2266782) | | | | | |
| G > A | | | | | |
| GG | 105 (71.92) | 4.00 (3.63-4.45) | Ref. | 2.330 (0.915-3.730) | Ref. |
| GA | 34 (23.29) | 3.91 (3.65-4.54) | 0.962 | 1.563 (0.750-4.160) | 0.525 |
| AA | 7 (4.79) | 3.48 (3.09-4.10) | 0.133 | 2.720 (0.970-5.530) | 0.762 |

Note: Ref., Reference (wild type).

<sup>a</sup>P-value was calculated using Kruskal-Wallis and Mann-Whitney U test. Comparison with GG or CC.

**FIGURE 1** Association between (A) voriconazole dose (mg/kg) (B) initial voriconazole trough concentration (µg/mL) and age group in Thai patients with invasive fungal infections (n = 177)
et al. 25 We found differences in voriconazole plasma concentrations in heterozygous carriers of the CYP2C19*2 allele compared to noncarriers in patients aged <12 years. However, the same association was not found in patients aged ≥12 years. This supports the voriconazole pharmacokinetic variability between children and adults previously addressed by Neely et al. 26 Contradictory results were recently reported in elderly patients. The authors reported that the median voriconazole concentration in patients with the CYP2C19*1/2 and CYP2C19*2/2 genotypes were significantly higher than those in patients with the CYP2C19*1/1 genotype. 27, 28 The voriconazole C0/dose was significantly associated with the CYP2C19*2 (rs4244285) polymorphism especially in patients aged <12 years. One possible reason is probably because the relative contribution of CYP2C19 enzymes in the formation of voriconazole N-oxide is 50% and 35% in children and adults, respectively. 6

Both CYP2C19*3 and CYP2C19*6 alleles included in our study are associated with reduced capability for metabolizing drugs. The frequencies of the CYP2C19*3 have a higher prevalence in Asian populations ranging from 2% to 9% compared to other major ethnic populations. In this study, we found that the incidence of CYP2C19*3 in Thai population (0.060) was similar to that found in East Asian populations (0.089). 21 The frequencies of the CYP2C19*6 allele in most populations are below 1% which was evident in our study population with a frequency of 0.3%. The CYP2C19*17 allele is a −806 C > T SNP that creates a consensus binding site for the GATA transcription factor family, resulting in increased gene transcription and high enzyme activities. 23 The CYP2C19*17 allele was observed with a prevalence of 0.8% among the Thai population in this study, which is lower than the previously reported frequency in the African (16%), American (18%), East Asian (2.7%), and European (21%) populations. 24

In Thai population, the FMO3 allele frequency was not reported. In our study, the minor allele frequency of FMO3 rs2266782 (E158K) in Thais was 0.160 that showed a lower frequency than in other ethnic populations. 17 Yamada et al reported an association between FMO3 rs2266782 (E158K) and lower plasma concentration of voriconazole. 7 In contrast, this study was not associated with the plasma concentration of voriconazole. In a previous study, He et al reported the association between CYP3A4 rs4646437 and higher plasma concentrations of voriconazole in Chinese. 22 In this study, the minor allele frequency of CYP3A4 rs4646437 was different from other ethnicities. The minor allele frequency in Thai population was higher than either that of Asians or Caucasians (0.26, 0.12 and 0.08 respectively). 29 In contrast, in this study we did not find any statistically significant association between CYP3A4 rs4646437 and plasma voriconazole concentrations.

To our knowledge, numerous variants of CYP3A4 have been described, but none of them can be held accountable for the high phenotypic variation observed. 30 In addition to CYP3A5, CYP3A5*3 is the major of CYP3A5 allele that found in all ethnic groups. 31, 32 To date, SNPs in CYP3A4 and CYP3A5 seem of limited importance to voriconazole. 24, 25 Weiss et al found no correlation between the CYP3A5*3 and voriconazole pharmacokinetics and Levin et al found that CYP3A5*3 was not associated with the liver toxicity that was caused due to voriconazole treatment. 33, 34 P-glycoprotein (P-gp) is encoded by the ABCB1 gene that is the most important drug efflux transporter and has been associated with voriconazole pharmacokinetics. Several SNPs have been reported in ABCB1 related to altered transport function of P-gp leading to interindividual variability in the pharmacokinetics of its substrates. In this study, the minor allele frequency of ABCB1rs1045642 (C3435T) in Thai was 0.36 that was lower than previously reported from other studies on the Thai population. 25

Most studies have focused on CYP2C19 and voriconazole disposition. We studied the polymorphisms in CYP3A4, FMO3, and ABCB1 and their impact on plasma voriconazole levels. We did not observe any significant association between these gene variants and plasma voriconazole levels in the patients aged <12 years and ≥12 years.

Several studies have demonstrated the relationship between treatment response and adverse events of voriconazole and its plasma concentrations. 10, 36, 37 The currently recommended voriconazole plasma level ranges for improved outcomes and minimized toxicities are in the range of 1.0-5.5 or 1.0-6.0 μg/mL. 38 Trough concentrations 1.0-6.0 μg/mL (within therapeutic range) were observed in 99% of the patients in our study. Considering the age effect on voriconazole dosing, pediatric patients need higher loading and maintenance dosing of voriconazole than in adult patients due to enhanced hepatic clearance and first-pass effect. 39 We found that the median voriconazole dose/weight was significantly lower in patients aged ≥12 years when compared to the patients aged <12 years (Figure 1).

Our study has some limitations. First, it was a retrospective and single-center study. Second, a small number of patients were included. Consequently, the CYP2C19*6 and *17 allele variants were absent in patients aged <12 years. Also, some homozygous mutations did not appear. Third, the focus of our study was on the influence of genetic polymorphisms in the CYP2C19, CYP3A4, FMO3, and ABCB1 genes (CYP2C19*2*3*6 and *17 CYP3A4 rs4646437, FMO3 rs2266782 and ABCB1 rs1045642) on voriconazole plasma concentrations, but the clinical outcome was not evaluated. Further studies are required to describe other clinically important SNPs of CYP2C19, CYP3A4, CYP3A5 and FMO3.

In conclusion, we report the frequency of CYP2C19 rs4244285, rs4986893, rs72552267, and rs12248560, CYP3A4 rs4646437, ABCB1 rs1045642, and FMO3 rs2266782 alleles in a Thai population and the involvement of these variants in the voriconazole plasma concentrations. Our data might support individual dose adjustment of voriconazole according to genetic polymorphisms of CYP2C19.

ETHICS STATEMENT

The study protocol was approved by the Hospital Ethics Committee of Ramathibodi Hospital, Mahidol University. All patients provided written informed consent. This study is registered in the Voriconazole Registry-Prospective cohort.
ACKNOWLEDGMENTS

This study was supported by grants from the (1) Faculty of Medicine, Ramathibodi Hospital, Mahidol University (2) The International Research Network-The Thailand Research Fund (IRN60W003), Thailand.

CONFLICT OF INTEREST

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

AUTHOR CONTRIBUTIONS

SC, CS and TJ were responsible for concept and design, analysis, interpretation of data, and final approval of the manuscript. SC and SM were responsible for data collection, preliminary analysis and drafting of the manuscript. SP and AP were responsible for laboratory consultation. SC, CS and TJ were responsible for supervising the overall conduct of the study.

DATA AVAILABILITY STATEMENT

Further information and requests for data should be directed to and will be fulfilled by the corresponding author, Chonlaphat Sukasem. Please contact chonlaphat.suk@mahidol.ac.th.

ORCID

Chonlaphat Sukasem https://orcid.org/0000-0002-7230-9766

REFERENCES

1. Wang T, Zhu H, Sun J, et al. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. Int J Antimicrob Agents. 2014;44:436-442.

2. Li X, Yu C, Wang T, Chen K, Zhai S, Tang H. Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2016;72:1185-1193.

3. Lin XB, Li ZW, Yan M, et al. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients. Br J Clin Pharmacol. 2018;84:1587-1597.

4. Mei H, Hu X, Wang J, Wang R, Cai Y. Determination of voriconazole in human plasma by liquid chromatography-tandem mass spectrometry and its application in therapeutic drug monitoring in Chinese patients. J Int Med Res. 2019:47(11):300060519887019.

5. Donnelly JP, De Pauw BE. Voriconazole-a new therapeutic agent with an extended spectrum of antifungal activity. Clin Microbiol Infect. 2004;10(Suppl 1):107-117.

6. Yanni SB, Annaert PP, Augustijns P, et al. Role of flavin-containing monoxygenase 3 in oxidative metabolism of voriconazole by human liver microsomes. Drug Metab Dispos. 2008;36:1119-1125.

7. Yamazaki H, Shimizu M. Survey of variants of human flavin-containing monoxygenase 3 (FMO3) and their drug oxidation activities. Biochem Pharmacol. 2013;85:1588-1593.

8. Promsas P, Puangthong A, Jenjirattithigarn N, et al. Development of a real-time PCR for CYP2C19*17 allele detection in Thai population. J Clin Pharmacol. 2015:55:5172-5177.

9. Yamada T, Mino Y, Naito T, Kawakami J. Impact of flavin-containing monoxygenase 3 and CYP2C19 genotypes on plasma disposition and adverse effects of voriconazole administered orally in immunocompromised patients. J Infect Chemother. 2019;25:1019-1025.

10. Hussaini T, Rüping MJGT, Farowski F, Vehreschild JJ, Cornely OA. Therapeutic drug monitoring of voriconazole and posaconazole. Pharmacotherapy. 2011;31:214-225.

11. Pratt VM, Del Tredici AL, Hachad H, et al. Recommendations for clinical CYP2C19 genotyping allele selection: a report of the association for molecular pathology. J Mol Diagn. 2018;20:269-276.

12. Ohtsuki S, Schaefer O, Kawakami H, et al. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos. 2012;40:83-92.

13. Murayama N, Imai N, Nakane T, Shimizu M, Yamazaki H. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol. 2007;73:2020-2026.

14. He HR, Sun JY, Ren XD, et al. Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole. Eur J Clin Microbiol Infect Dis. 2015;34:811-819.

15. Allegra S, Fatiguso G, Francia SD, et al. Pharmacogenetic of voriconazole anti fungal agent in pediatric patients. Pharmacogenomics. 2018;19:913-925.

16. Yanni SB, Annaert PP, Augustijns P, et al. Role of flavin-containing monoxygenase 3 in oxidative metabolism of voriconazole by human liver microsomes. Drug Metab Dispos. 2008;36:1119-1125.

17. Yamazaki H, Shimizu M. Survey of variants of human flavin-containing monoxygenase 3 (FMO3) and their drug oxidation activities. Biochem Pharmacol. 2013;85:1588-1593.

18. Chaudhry AS, Prasad B, Shirasaka Y, et al. The CYP2C19 intron 2 CYP2C19*2 alleles. Drug Metab Dispos. 2015;43:1226-1235.

19. Scott SA, Sangkuhl K, Gardner EE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 and clinical pharmacodynamics in children. Clin Infect Dis. 2010;50:27-36.
27. Shang S, Cheng L, Li X, et al. Effect of CYP2C19 polymorphism on the plasma voriconazole concentration and voriconazole-to-voriconazole N-oxide concentration ratio in elderly patients. *Mycoses*. 2020.

28. Chuwongwattana S, Jantararoungtong T, Chitasombat MN, et al. A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis. *Drug Metab Pharmacokinet*. 2016;31:117-122.

29. Shao B, Ma Y, Li Q, et al. Effects of cytochrome P450 3A4 and non-genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes. *Xenobiotica*. 2017;47:1121-1129.

30. Mikus G, Scholz IM, Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole. *Pharmacogenomics*. 2011;12:861-872.

31. Schuetz EG, Relling MV, Kishi S, et al. PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5. *Pharmacol Rev*. 2004;56:159.

32. Daly AK. Significance of the minor cytochrome P450 3A isoforms. *Clin Pharmacokinet*. 2006;45:13-31.

33. Weiss J, Ten Hoevel MM, Burhenne J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. *J Clin Pharmacol*. 2009;49:196-204.

34. Levin M-D, den Hollander JG, Van Der Holt B, et al. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. *J Antimicrob Chemother*. 2007;60:1104-1107.

35. Singkham N, Avihingsanon A, Bunupuradah T, Punyawudho B. Genotype and allele frequencies of ABCB1 and SLCO1B1 polymorphisms in THAI HIV-infected patients. *Chulalongkorn Med J*. 2018;62:697-709.

36. Seyedmousavi S, Mouton JW, Verweij PE, Brüggemann RJ. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. *Expert Rev Anti Infect Ther*. 2013;11:931-941.

37. Cabral-Galeano E, Ruiz-Camps I, Len-Abad O, et al. Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital. *Enferm Infeccc Microbiol Clin*. 2015;33:298-302.

38. Yi WM, Schoeppler KE, Jaeger J, et al. Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study. *Ann Clin Microbiol Antimicrob*. 2017;16:60.

39. Allegra S, Fatiguso G, De Francia S, et al. Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children. *Br J Clin Pharmacol*. 2018;84:197-203.

How to cite this article: Chuwongwattana S, Jantararoungtong T, Prommas S, Medhasi S, Puangpetch A, Sukasem C. Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections. *Pharmacol Res Perspect*. 2020;e00665. [https://doi.org/10.1002/prp2.665](https://doi.org/10.1002/prp2.665)